Perstorp signs license and collaboration agreement with Polymer Factory
Dendritic materials can be tailored to suit the most various needs. Polymer Factory's CEO Mats Wallnér believes that there is a bright future for these nanometer-sized building blocks in biomedical applications, for example as carriers of active substances in medicines. The active substances can be incorporated in the dendrimer structure and thereby improve solubility and reduce toxicity problems. Inside the body the dendrimers can release the active substances where it is needed most, Wallnér says. Another example, where Polymer Factory is conducting extensive research, is for advanced diagnostic methods such as in vitro tests for allergy towards pharmaceuticals.
Most read news
Other news from the department business & finance
Get the chemical industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.